Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 49Lung Neoplasms 12Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Neoplasm Metastasis 7Multiple Myeloma 6Lymphoma 6Granuloma, Plasma Cell 4Colorectal Neoplasms 4Adenocarcinoma 4Uveal Melanoma 3Neuroblastoma 3Melanoma 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Glioma 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2ALK-positive NSCLC 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Nivolumab 20Ipilimumab 10Surveys and Questionnaires 7Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Interviews as Topic 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancer × Crizotinib × Clear all
NCT01576406 2018-10-25

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Pfizer

Phase 1 Completed
88 enrolled 44 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡